Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 44Recurrence 9Sarcoma, Kaposi 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2Plasmacytoma 1Plasmablastic Lymphoma 1Multi-centric Castleman's Disease 1Malignant Plasma Cell Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 28Rituximab 23fludarabine 14fludarabine phosphate 12Specimen Handling 11obinutuzumab 10ibrutinib 10Magnetic Resonance Spectroscopy 10Prednisone 8Doxorubicin 8tocilizumab 7polatuzumab vedotin 7X-Rays 7Whole-Body Irradiation 7Phantoms, Imaging 7Mycophenolic Acid 7Etoposide 7Biopsy 7venetoclax 6glofitamab 6Melphalan 6Lenalidomide 6Bendamustine Hydrochloride 6pirtobrutinib 5acalabrutinib 5Vincristine 5Peripheral Blood Stem Cell Transplantation 5Nuclear Medicine Department, Hospital 5Nivolumab 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Non-Hodgkin × pomalidomide × 90 days × Clear all
NCT05389423 2026-06-01

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
25 enrolled
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡